Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rhythm Pharmaceuticals (RYTM) Long-Term Investments (2021 - 2025)

Rhythm Pharmaceuticals (RYTM) has disclosed Long-Term Investments for 5 consecutive years, with $3.3 million as the latest value for Q4 2025.

  • Quarterly Long-Term Investments fell 55.15% to $3.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $3.3 million through Dec 2025, down 55.15% year-over-year, with the annual reading at $3.3 million for FY2025, 55.15% down from the prior year.
  • Long-Term Investments for Q4 2025 was $3.3 million at Rhythm Pharmaceuticals, up from $2.5 million in the prior quarter.
  • The five-year high for Long-Term Investments was $18.4 million in Q1 2022, with the low at $2.2 million in Q2 2025.
  • Average Long-Term Investments over 5 years is $11.8 million, with a median of $13.3 million recorded in 2024.
  • The sharpest move saw Long-Term Investments surged 48.26% in 2022, then crashed 82.59% in 2025.
  • Over 5 years, Long-Term Investments stood at $11.8 million in 2021, then surged by 40.96% to $16.7 million in 2022, then fell by 9.94% to $15.0 million in 2023, then tumbled by 51.16% to $7.3 million in 2024, then crashed by 55.15% to $3.3 million in 2025.
  • According to Business Quant data, Long-Term Investments over the past three periods came in at $3.3 million, $2.5 million, and $2.2 million for Q4 2025, Q3 2025, and Q2 2025 respectively.